Results 31 to 40 of about 37,535,730 (255)
Pediatric Blood &Cancer, EarlyView.ABSTRACT Pediatric intramedullary low‐grade gliomas (PIMLGGs) are rare neoplasms that present unique clinical and management challenges. Although surgery remains the primary tool for tissue diagnosis and decompression, complete gross‐total resection is frequently unfeasible due to the infiltrative nature of these lesions.
Olga M. Sergeenko +5 more
wiley +1 more source
Engineering peptides into antibodies—opportunities and strategies for therapeutic innovation
FEBS Letters, EarlyView.Peptides and antibodies occupy complementary therapeutic niches. Peptides recognize difficult targets in a compact format, while antibodies add specificity, long half‐life, and effector functions. This review examines strategies that merge both modalities—peptide grafting into loops, terminal and Fc fusions, and bioconjugation—highlighting how ...
Jinling Wang +2 more
wiley +1 more source
Barbara Epstein, AHIP, FMLA, Medical Library Association President, 2017–2018 [PDF]
, 2017 A profile of Barbara Epstein, AHIP, FMLA, Medical Library Association President, 2017 ...
Kelly Gonzalez, Gonzalez, Kelly
core +1 more source
Inhibition of dipeptidyl peptidase 7 impairs lysophagy in LLOMe‐treated HepG2 cells
FEBS Letters, EarlyView.DPP7 inhibition delays ubiquitin‐dependent lysophagy by attenuating ubiquitin accumulation and the recruitment of SQSTM1 and LC3 to damaged lysosomes, resulting in delayed clearance of damaged lysosomes and impaired restoration of lysosomal homeostasis. Created using FigureLabs (Certificate ID: FL‐PUB‐20260922‐Z99XNX).
Na Yeon Park +8 more
wiley +1 more source
Going viral − Virus‐targeting nanobodies for research, diagnostics and therapy
FEBS Letters, EarlyView.The increasing prevalence of viral diseases represents a major threat for global human health. Nanobodies, small binding fragments derived from camelid heavy‐chain antibodies, offer versatile tools for viral research, diagnostics, and antiviral therapy.
Domenic Ebert, Ulrich Rothbauer
wiley +1 more source
Unlocking the potential of cell‐permeable nanobodies for intracellular applications
FEBS Letters, EarlyView.This review outlines current strategies for delivery of nanobodies into cells and highlights recent examples of functional applications. By addressing and manipulating intracellular targets, these molecules hold great potential for treating cancer, respiratory diseases and neurological disorders, making this a vibrant area of research in the biomedical
Mariona Gené‐Verdés +2 more
wiley +1 more source
KDM7A and KDM1A inhibition suppresses tumour promoting pathways in prostate cancer
Molecular Oncology, EarlyView.Treatment resistance is a major challenge for patients with advanced prostate cancer. This study examined an alternative approach to target the major prostate cancer‐promoting pathway by targeting epigenetic factors, whose levels are higher in tumours.
Jennie N Jeyapalan +16 more
wiley +1 more source
GMS Medizin – Bibliothek – InformationThe 2024 conference in Mainz is reported on and thoughts for the future development of the conference are discussed.
Jirausch, Claudia
doaj +3 more sources
AGMB 2023: Zukunft – jetzt erst recht
GMS Medizin – Bibliothek – Information, 2023 The 2023 annual conference of the German Medical Libraries Association (AGMB) in Bonn was held under the motto “AGMB 2023: Future – now more than ever”. There were numerous lectures and short presentations, posters and workshops.
Reimann, Iris
doaj +1 more source
Molecular Oncology, EarlyView.Combining osimertinib with the STING agonist ADU‐S100 activates innate and adaptive immunity to overcome the non‐inflamed microenvironment of Egfr‐mutant lung cancer. This combination increases NK and CD8+ T‐cell infiltration, associated with activation of the STING‐IRF3 pathway and local immunogenic cell death.
Jun Nishimura +19 more
wiley +1 more source